A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers
BACKGROUND: Buffy coats are becoming less available as a source of research‐grade peripheral blood mononuclear cells (PBMNCs). Therefore, alternative sources of these cells were investigated. STUDY DESIGN AND METHODS: PBMNCs isolated from the cells retained in leukoreduction system chambers (LRSCs)...
Saved in:
Published in | Transfusion (Philadelphia, Pa.) Vol. 46; no. 12; pp. 2083 - 2089 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Malden, USA
Blackwell Publishing Inc
01.12.2006
Blackwell Publishing |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | BACKGROUND: Buffy coats are becoming less available as a source of research‐grade peripheral blood mononuclear cells (PBMNCs). Therefore, alternative sources of these cells were investigated.
STUDY DESIGN AND METHODS: PBMNCs isolated from the cells retained in leukoreduction system chambers (LRSCs) and those eluted from white blood cell filters were compared. From LRSCs (1.88 ± 0.40) × 109 PBMNCs (n = 13) versus (0.43 ± 0.15) × 109 PBMNCs were isolated from leukofilter eluates (LFEs, n = 8; p < 0.0001).
RESULTS: Cells from LRSCs and LFEs produced similar numbers of burst‐forming unit–erythroid, colony‐forming unit (CFU)–granulocyte‐macrophage, and CFU–granulocyte‐erythrocyte‐monocyte‐macrophage‐megakaryocyte colonies. The percentages of cells positive for CD3, CD4, CD8, CD14, CD19, and CD56 in the PBMNCs isolated from LRSCs and LFEs were indistinguishable. Cells isolated from LRSCs expressed higher levels of CD69 and CD25 in reaction to staphylococcal enterotoxin B than the cells isolated from LFEs. The source of cells affected neither the yield and purity of immunomagnetically isolated CD3+ cells, CD14+ cells, and CD56+ cells nor the function of T cells, natural killer cells, and in vitro matured dendritic cells (DCs). DC yield from LRSC‐derived CD14+ cells, however, was higher.
CONCLUSION: LRSCs are a novel source of fully functional PBMNCs that can replace the more traditional sources of research‐grade cellular products. |
---|---|
Bibliography: | ark:/67375/WNG-9PSKKRW1-Z istex:BFD79666EF682F3995F8851ABC6C629E2BF8E72E ArticleID:TRF01033 Supported by NIH Grant R01CA‐84368, Mayo Clinic Comprehensive Cancer Center Support Grant CA‐15083, and NIH Grant P50 CA‐108961‐01. Stem Cell Laboratory has been supported by Mrs. Adelyn L. Luther, Singer Island, FL; Commonwealth Cancer Foundation for Research, Richmond, VA; and Glen and Florence Voyles Foundation, Terre Haute, IN. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0041-1132 1537-2995 |
DOI: | 10.1111/j.1537-2995.2006.01033.x |